

PATENT

I hereby certify that, on the date shown below, this correspondence is being:

deposited with the United States Postal Service in an envelope addressed to: BOX MISSING PARTS, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231,
 under 37CFR § 1.8(a), with sufficient postage as first class mail, or
 under 37CFR § 1.10, as "Express Mail Post Office to Addressee" Mailing Label No.

transmitted by facsimile to the Patent and Trademark Office, Fax Number _____
 Attention: Examiner _____

Date: July 17, 2001 By: Lois E. Miller

Attorney Docket No.
 DX0724XK
 CN 028008

1046 U.S. PTO
 09/950041



09/10/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gerard T. Hardiman, *et al.*

Serial No.: 09/728,540

Filed: November 28, 2000

For: HUMAN RECEPTOR PROTEINS;
 RELATED REAGENTS AND
 METHODS

Examiner: not yet assigned

Art Unit: 1653

COMPUTER READABLE SEQUENCE
 SUBMISSION

Palo Alto, California 94304

July 16, 2001

5 5 BOX Missing Parts
 Assistant Commissioner for Patents
 Washington, D.C. 20231

Sir:

10 COMPLIANCE WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
 NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

15 In reply to receipt of a "Notice to Comply" with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures dated June 7, 2001, for the above-identified application, in accordance with 37 CFR § 1.821 - 1.825, Applicants hereby submit: (1) a write-protected diskette containing a computer-readable submission for the "Sequence Listing"; and (2) a "Sequence Listing" paper copy of the contents of the diskette.

20 REMARKS


25 Enclosed is a write protected floppy diskette with the sequence listing generated by the Patent Office's PATENTIN 2.0 program. The Diskette should comply with the requirements of 37 CFR § 1.824 and is IBM PC compatible with a PC-DOS/MS-DOS operating system. If the diskette has been damaged, please call Applicants and a replacement diskette will be provided. A hard paper copy printout of the diskette is attached thereto.

I hereby state the informational contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are believed to be the same. This submission introduces no new matter, since enclosed sequences are the same as sequences which were submitted in priority documents.

5 Applicants have invested over ten hours of significant labor and care in preparing the present submission. The enclosed items are a bona fide effort to bring the present application into full compliance with the rules for sequence submissions. Should this not be the case, Applicants respectfully request notification of specific deficiencies and an opportunity for remedy, as described in 37 CFR 1.135(c).

10 Applicants believe that no fees are required; however, if any fees are required by the present Response, the Commissioner is authorized to charge any fees or credit any overpayment to DNAX Research Institute Deposit Account No. 04-1239.

15 Respectfully submitted,

20 Date: July 16, 2001 By: 
Sheela Mohan-Peterson
Attorney for Applicants
Reg. No. 41,201

25 enclosures and attachments:
one write-protected diskette (CRM)
paper copy of contents of diskette
copy of notice to comply

30 DNAX Research Institute
901 California Avenue
Palo Alto, California 94304-1104
Main: (650) 852-9196
35 Direct: (650) 496-1244
Fax: (650) 496-1200

I hereby certify that, on the date shown below, this correspondence is being:

deposited with the United States Postal Service in an envelope addressed to:
ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231,
 under 37CFR § 1.8(a), with sufficient postage as first class mail, or
 under 37CFR § 1.10, as "Express Mail Post Office to Addressee" Mailing Label No.
EL 367 647 761 US.
 transmitted by facsimile to the Patent and Trademark Office, Fax Number _____
Attention: Examiner _____, Art Unit 16xx

PATENT

Attorney Docket No.
DX0724XK1

CN 028008

Date: September 10, 2001 By: Jeffrey Gillis
Jeffrey Gillis

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gerard T. HARDIMAN, et al.

Serial No.: to be assigned

Filed: SEPTEMBER 10, 2001

For: HUMAN RECEPTOR PROTEINS;
RELATED REAGENTS AND
METHODS

Examiner: not assigned

Art Unit: not assigned

USE OF PRIOR SEQUENCE
SUBMISSION UNDER 37 CFR §1.821(e)

Palo Alto, California 94304

SEPTEMBER 10, 2001

5

Assistant Commissioner for Patents
Box: Patent Application
Washington, D.C. 20231

10

Sir:

15

The attached copy of the Sequence Submission is for the patent application submitted herewith. The computer readable form in this application is equivalent to that filed in parent application USSN 09/728,540. In accordance with 37 CFR 1.821(e), please use the computer readable form submitted in that application on July 17, 2001, as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for computer readable form that will be used for the instant application.

20

The attached copy of the Sequence Submission was originally submitted to the patent office in the parent application, USSN 09/728,540, in response to the Notice to Comply with Requirements for Patent Applications containing Nucleotide and/or Amino Acid Sequences dated June 7, 2001, for incorporation into the specification, on July 17, 2001.

Respectfully submitted,

By: Sheela Mohan-Peterson
Sheela Mohan-Peterson
Attorney for Applicants
Reg. No. 41,201

Dated: September 10, 2001

**DNAX Research Institute
901 California Avenue
Palo Alto, California 94304-1104
Tel: (650) 496-6400
Fax: (650) 496-1200**



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/728,540	11/28/2000	Gerard T. Hardiman	DX0724XK

CONFIRMATION NO. 4490

28008
DNAX RESEARCH INSTITUTE
LEGAL DEPARTMENT
901 CALIFORNIA AVENUE
PALO ALTO, CA 94304

FORMALITIES LETTER



OC00000006158487

Date Mailed: 06/07/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov